- Chronic iron overload due to blood transfusions.
- Chronic iron overload in non-transfusion dependent thalassemia syndromes in patients with a liver iron concentration of
5 mg/g of liver dry weight and a serum ferritin >300 mcg/L.
5 mg/g of liver dry weight and a serum ferritin >300 mcg/L.Contraindicated in:
Use Cautiously in:
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, rash.
EENT: cataracts, hearing loss, ↑ intraocular pressure, lens opacities, retinal disorders.
GI: GI BLEEDING/ULCERATION, GI PERFORATION, HEPATOTOXICITY, diarrhea, nausea , vomiting, abdominal pain, drug-induced hepatitis, ↑ liver enzymes.
GU: RENAL FAILURE, ↑serum creatinine, renal failure.
Hemat: agranulocytosis, neutropenia, thrombocytopenia, worsening anemia.
MS: arthralgia.
Neuro: headache, dizziness.
Resp: cough.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA), fever.
Drug-Drug:
(Generic available)
Chronic Iron Overload Due to Blood Transfusions
2 yr): Exjade — 20 mg/kg once daily; adjusted by 5–10 mg/kg every 3–6 mo on the basis of serum ferritin levels (not to exceed 40 mg/kg/day); Jadenu — 14 mg/kg once daily; adjusted by 3.5–7 mg/kg every 3–6 mo on the basis of serum ferritin levels (not to exceed 28 mg/kg/day).Hepatic Impairment
2 yr): Moderate hepatic impairment (Child-Pugh B) — ↓initial dose by 50%.Renal Impairment
2 yr): CCr 40–60 mL/min — ↓initial dose by 50%.Chronic Iron Overload in Non-Transfusion Dependent Thalassemia Syndromes
10 yr): Exjade — 10 mg/kg once daily; if baseline liver iron concentration >15 mg/g of liver dry weight, consider ↑ dose to 20 mg/kg/day after 4 wk. If liver iron concentration remains >7 mg/g of liver dry weight after 6 mo, ↑ dose to 20 mg/kg/day (maximum dose). If liver iron concentration is 3–7 mg/g of liver dry weight after 6 mo, continue therapy with no more than 10 mg/kg/day. When liver iron concentration <3 mg/g of liver dry weight, may discontinue therapy (restart when liver iron concentration >5 mg/g of liver dry weight); Jadenu — 7 mg/kg once daily; if baseline liver iron concentration >15 mg/g of liver dry weight, consider ↑ dose to 14 mg/kg/day after 4 wk. If liver iron concentration remains >7 mg/g of liver dry weight after 6 mo, ↑ dose to 14 mg/kg/day (maximum dose). If liver iron concentration is 3–7 mg/g of liver dry weight after 6 mo, continue therapy with no more than 7 mg/kg/day. When liver iron concentration <3 mg/g of liver dry weight, may discontinue therapy (restart when liver iron concentration >5 mg/g of liver dry weight).Hepatic Impairment
10 yr): Moderate hepatic impairment (Child-Pugh B) — ↓initial dose by 50%.Renal Impairment
2 yr): CCr 40–60 mL/min — ↓initial dose by 50%.Absorption: Well absorbed (70%) following oral administration, absorption is less in children.
Distribution: Unknown.
Protein Binding: 99%.
Metabolism/Excretion: Mostly metabolized by the liver, followed by enterohepatic recycling. 84% excreted in feces (deferasirox and metabolites); minimal renal excretion.
Half-life: 8–16 hr.
NDC Code*
